Ironwood Pharmaceuticals Stock Cash And Equivalents
| IRWD Stock | USD 8.28 0.06 0.73% |
Ironwood Pharmaceuticals fundamentals help investors to digest information that contributes to Ironwood Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Ironwood Stock. The fundamental analysis module provides a way to measure Ironwood Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Ironwood Pharmaceuticals stock.
Ironwood | Cash And Equivalents |
Ironwood Pharmaceuticals Company Cash And Equivalents Analysis
Ironwood Pharmaceuticals' Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Current Ironwood Pharmaceuticals Cash And Equivalents | 504.36 M |
Most of Ironwood Pharmaceuticals' fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Ironwood Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Ironwood Cash And Equivalents Driver Correlations
Understanding the fundamental principles of building solid financial models for Ironwood Pharmaceuticals is extremely important. It helps to project a fair market value of Ironwood Stock properly, considering its historical fundamentals such as Cash And Equivalents. Since Ironwood Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Ironwood Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Ironwood Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
| Competition |
Ironwood Cash And Cash Equivalents Changes
Cash And Cash Equivalents Changes |
|
In accordance with the recently published financial statements, Ironwood Pharmaceuticals has 504.36 M in Cash And Equivalents. This is 38.56% lower than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The cash and equivalents for all United States stocks is 81.33% higher than that of the company.
Ironwood Cash And Equivalents Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Ironwood Pharmaceuticals' direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Ironwood Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Ironwood Pharmaceuticals by comparing valuation metrics of similar companies.Ironwood Pharmaceuticals is currently under evaluation in cash and equivalents category among related companies.
Ironwood Fundamentals
| Return On Equity | -6.74 | ||||
| Return On Asset | 0.13 | ||||
| Profit Margin | (2.26) % | ||||
| Operating Margin | 0.03 % | ||||
| Current Valuation | 1.84 B | ||||
| Shares Outstanding | 158.96 M | ||||
| Shares Owned By Insiders | 1.73 % | ||||
| Shares Owned By Institutions | 98.27 % | ||||
| Number Of Shares Shorted | 21.16 M | ||||
| Price To Earning | 18.35 X | ||||
| Price To Book | 2.59 X | ||||
| Price To Sales | 2.79 X | ||||
| Revenue | 442.74 M | ||||
| Gross Profit | 366.33 M | ||||
| EBITDA | 210.61 M | ||||
| Net Income | (1 B) | ||||
| Cash And Equivalents | 504.36 M | ||||
| Cash Per Share | 3.29 X | ||||
| Total Debt | 715.54 M | ||||
| Debt To Equity | 0.78 % | ||||
| Current Ratio | 26.52 X | ||||
| Book Value Per Share | (2.21) X | ||||
| Cash Flow From Operations | 183.43 M | ||||
| Short Ratio | 5.44 X | ||||
| Earnings Per Share | (6.45) X | ||||
| Price To Earnings To Growth | (0.26) X | ||||
| Target Price | 18.0 | ||||
| Number Of Employees | 267 | ||||
| Beta | 0.55 | ||||
| Market Capitalization | 1.23 B | ||||
| Total Asset | 471.07 M | ||||
| Retained Earnings | (1.7 B) | ||||
| Working Capital | (42.81 M) | ||||
| Current Asset | 500.2 M | ||||
| Current Liabilities | 76.47 M | ||||
| Net Asset | 471.07 M |
About Ironwood Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Ironwood Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ironwood Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ironwood Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Ironwood Pharmaceuticals Piotroski F Score and Ironwood Pharmaceuticals Altman Z Score analysis. For information on how to trade Ironwood Stock refer to our How to Trade Ironwood Stock guide.You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Complementary Tools for Ironwood Stock analysis
When running Ironwood Pharmaceuticals' price analysis, check to measure Ironwood Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ironwood Pharmaceuticals is operating at the current time. Most of Ironwood Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Ironwood Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ironwood Pharmaceuticals' price. Additionally, you may evaluate how the addition of Ironwood Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon |
Is Ironwood Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ironwood Pharmaceuticals. If investors know Ironwood will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ironwood Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.69) | Earnings Share (6.45) | Revenue Per Share 2.848 | Quarterly Revenue Growth 0.097 | Return On Assets 0.1339 |
The market value of Ironwood Pharmaceuticals is measured differently than its book value, which is the value of Ironwood that is recorded on the company's balance sheet. Investors also form their own opinion of Ironwood Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Ironwood Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ironwood Pharmaceuticals' market value can be influenced by many factors that don't directly affect Ironwood Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ironwood Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ironwood Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ironwood Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.